Wall Street Zen Upgrades Vicore Pharma (NASDAQ:VCRE) to Hold

Vicore Pharma (NASDAQ:VCRE) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research analysts have also issued reports on the company. Weiss Ratings began coverage on Vicore Pharma in a research report on Thursday, October 8th. They set a “sell (e-)” rating for the company. Jefferies Financial Group began coverage on Vicore Pharma in a research report on Friday, October 9th. They issued a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

Vicore Pharma Stock Performance

VCRE stock opened at $9.38 on Friday. Vicore Pharma has a 52-week low of $7.88 and a 52-week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last issued its quarterly earnings results on Friday, August 21st. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.23 million for the quarter.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.